Chloramphenicol: Uses, Doses and Safety

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

Chloramphenicol is a broad-spectrum bacteriostatic antibiotic that binds the 50S ribosomal subunit and blocks bacterial protein synthesis. It is a prescription-only drug. Its spectrum covers many gram-positive bacteria, gram-negative bacteria, anaerobes and rickettsia, which once made chloramphenicol antibiotics a dependable choice for serious infections in dogs, cats and other species. In the United States and many other countries, its use in food-producing animals is banned or tightly restricted because of human safety concerns, principally idiosyncratic aplastic anemia and, in human infants, grey baby syndrome. Florfenicol is the fluorinated veterinary analog developed to avoid that mechanism of human toxicity, and it has largely replaced chloramphenicol in livestock practice where treatment is still needed.

The drug divides veterinarians into two camps. Some continue to use chloramphenicol for specific clinical situations, particularly where anaerobic or central nervous system infection is suspected and no safer alternative is available. Others avoid it entirely because the human hematologic risk, however rare, is not reversible and does not depend on dose. This article lays out the mechanism, the label uses, the dosing table with extra-label flags, the handler warnings, and the resistance picture so you can make a defensible decision with your veterinarian.

This article is educational and is not a substitute for veterinary diagnosis or treatment.

At a Glance

What Chloramphenicol Is and How It Works

Chloramphenicol is a small, highly lipophilic molecule, which is why it distributes widely into tissues, crosses cell membranes easily, and reaches the central nervous system and intracellular compartments better than many older antibiotics. That pharmacokinetic profile is the main reason it still appears in veterinary formularies despite its safety reputation.

The drug works by binding reversibly to the 50S subunit of the bacterial ribosome. That subunit contains the peptidyl transferase center, the enzyme activity that forms peptide bonds between adjacent amino acids in the growing protein chain. When chloramphenicol occupies the binding site, the ribosome can still position the aminoacyl-tRNA but cannot efficiently catalyze the peptide bond. Protein synthesis stalls. Because the binding is reversible, the effect is bacteriostatic rather than bactericidal in most situations, meaning the drug stops bacteria from multiplying but relies on host immunity to clear them. This is a key clinical point: chloramphenicol works best in patients with functional immune defenses, and it is less reliable as monotherapy in severely immunosuppressed animals or in infections where bacterial clearance depends heavily on a bactericidal effect (for example, endocarditis).

Chloramphenicol has been studied for its biotransformation in environmental systems, where microbial communities degrade it through oxidation at the C1 and C3 hydroxyl groups, isomerization at C2, and acetylation at C3-OH [1]. This environmental work is not directly clinical, but it illustrates how widely the molecule spreads once released and why agricultural use has such a strong resistance and ecologic footprint.

Spectrum of Activity

The spectrum is genuinely broad, and this is one reason chloramphenicol antibiotics remain attractive in resource-limited settings. Chloramphenicol covers:

• Gram-positive bacteria. Including many Staphylococcus species, Streptococcus species, and Bacillus species.
• Gram-negative bacteria. Including Escherichia coli, Klebsiella species, Salmonella species, and Haemophilus species.
• Anaerobes. Including Bacteroides species and Clostridium species, which is one of its distinguishing features compared with many older antibiotics.
• Rickettsia. Including the agents of Rocky Mountain spotted fever and ehrlichiosis, though doxycycline is generally preferred now.
• Some spirochetes and Mycoplasma species. Activity is variable and should not be assumed without susceptibility testing.

Coverage does not reliably extend to Pseudomonas aeruginosa, which is intrinsically resistant through efflux and outer membrane permeability barriers [2]. Enterococcus species are often resistant or only marginally susceptible. Methicillin-resistant Staphylococcus aureus varies widely by strain and region, and many MRSA isolates carry chloramphenicol acetyltransferase or efflux determinants.

Mechanism of Resistance

Two resistance mechanisms dominate in clinical isolates.

Enzymatic inactivation by chloramphenicol acetyltransferase (CAT). CAT enzymes acetylate the 3-hydroxyl group of chloramphenicol, which prevents the drug from binding the ribosome. The genes encoding these enzymes, commonly abbreviated cat, are frequently plasmid-borne and can spread horizontally between bacterial species. Work in Malawian Enterobacterales showed that many phenotypically susceptible isolates still carry cat genes, meaning genotype and phenotype can disagree in up to 31% of isolates in some settings [3]. That discordance matters because a laboratory report of susceptibility does not guarantee the absence of a resistance determinant that could be selected under therapy.

Efflux pumps. The AcrAB-TolC efflux system in E. coli is a major intrinsic resistance pathway for chloramphenicol. Knockout of acrB produces hypersusceptibility to chloramphenicol and several other chemically unrelated antibiotics [2]. Efflux is also a common acquired mechanism in other species. In staphylococci, efflux and enzymatic inactivation both contribute to chloramphenicol resistance, alongside the broader resistance mechanisms cataloged across the genus [4].

Resistance prevalence in clinical veterinary isolates tracks usage pressure. Surveys from poultry production have documented chloramphenicol resistance in roughly 41% of gram-negative isolates from broiler cecal contents in one regional study [5], and 48.9% resistance was reported among gram-negative fish farm isolates in another [6]. The pattern is consistent: where chloramphenicol or related amphenicols are used heavily in animal production, resistance genes accumulate.

Labeled and Extra-Label Uses in Veterinary Medicine

Chloramphenicol has historically been labeled in veterinary practice for a range of infections, including:

• Bacterial pneumonia and other respiratory infections.
• Enteritis and other gastrointestinal infections, particularly where anaerobes are suspected.
• Urinary tract infections.
• Skin and soft tissue infections.
• Ophthalmic infections, most commonly as a topical ointment or solution.
• Otitis externa and media.
• Central nervous system infections, including meningitis, because of its excellent penetration into the cerebrospinal fluid.

The table below lists common veterinary indications with representative doses drawn from label and standard veterinary formulary sources. Every entry is a drug that requires a prescription and, where the label does not cover the species or indication, is extra-label. Extra-label use in the US requires a valid veterinarian-client-patient relationship and must follow the AMDUCA framework.

Doses above reflect common veterinary formulary values and are provided for educational discussion. Because chloramphenicol has a narrow margin between therapeutic effect and human hematologic risk, dosing decisions for any individual animal should come from a veterinarian who knows the case. This is not a substitute for professional veterinary guidance.

How to Give Chloramphenicol

Oral chloramphenicol is usually given with food to reduce nausea and stomach upset. Capsules should be swallowed whole with a small amount of food or a treat, and oral suspension should be shaken well before measuring. Do not mix the drug into a full meal if the animal may not finish it, because the dose will be unreliable.

The drug is bitter and can cause drooling, lip smacking, or vomiting in cats and dogs when the capsule is punctured before administration. If a dose is vomited within 20 to 30 minutes, the veterinarian may recommend repeating it. Never repeat a dose without asking, because chloramphenicol is not a drug to overexpose the patient to.

Ophthalmic ointment is applied by pulling the lower eyelid down to form a pocket, squeezing a thin ribbon along the inside of the lid, and allowing the animal to blink it into place. Wipe the tip of the tube after each use with a clean tissue to avoid contaminating the container.

The topical form is well tolerated in most animals. A systematic review of topical chloramphenicol ointment for surgical wounds found evidence of a non-statistically significant reduction in infection rates, and reported delayed hypersensitivity and acute esophagitis as potential side effects, with no cases of aplastic anemia reported in the reviewed topical data [7]. That is a useful contrast with systemic use, though it does not make topical use risk-free.

If the animal misses a dose, give it as soon as you remember. If it is nearly time for the next dose, skip the missed dose and continue on schedule. Never double up.

Side Effects and What to Do

Chloramphenicol's side effect profile depends heavily on route, dose, and duration.

Common and Reversible Effects

• Gastrointestinal upset. Vomiting, diarrhea, and reduced appetite are the most common reasons owners report a problem. Splitting the dose with a meal usually helps.
• Local reactions with topical use. Redness, stinging, or a transient increase in discharge can occur with ophthalmic preparations.
• Delayed hypersensitivity. Reported with topical ointment use on surgical wounds [7].

Serious Effects

• Dose-dependent bone marrow suppression. This is a reversible suppression of red cell, white cell, and platelet production, and it is more likely with high doses or prolonged courses. It shows up on a complete blood count as a falling hematocrit, leukopenia, or thrombocytopenia. Monitoring a CBC during therapy is standard practice in animals receiving systemic chloramphenicol, particularly after two weeks of treatment.
• Irreversible idiosyncratic aplastic anemia. This is the human safety issue that dominates the drug's regulatory status. It is not dose-dependent and can occur at any dose. Epidemiologic studies have produced mixed results. One case-control study in Latin America found that individuals exposed to chloramphenicol in the previous year had an adjusted odds ratio for aplastic anemia of 8.7 (95% CI 0.87 to 87.93), which is a wide confidence interval that straddles 1 and does not reach statistical significance [8]. A separate Brazilian study found no positive association (OR 0.4, 95% CI 0.1 to 2.9) [9], and a Thai study found chloramphenicol use was infrequent and showed no significant association with aplastic anemia [10]. The signals are inconsistent, but the historical human case series and the biological plausibility are strong enough that the regulatory precaution stands in most jurisdictions.
• Grey baby syndrome. A distinct human neonatal toxicity that produces cardiovascular collapse, abdominal distension, and a characteristic grey skin color. It results from immature hepatic glucuronidation and immature renal excretion in newborns, and it is the reason chloramphenicol is contraindicated in human infants. This mechanism does not translate directly to veterinary species, but it does highlight that neonates of any species may handle the drug differently than adults.
• Neurotoxicity. Rare, usually optic neuritis or peripheral neuropathy with prolonged human use. Reported infrequently in animals.

What to Do

Stop the drug and contact the veterinarian if you see pale gums, persistent vomiting, a fever that develops during treatment, unexplained bruising, or a sudden drop in energy. Do not wait for the next scheduled appointment if these signs appear. For mild stomach upset, call the clinic and ask whether the dose can be split or given with a bland meal.

Which Animals Should Not Receive Chloramphenicol

Chloramphenicol is contraindicated or used with extreme caution in:

• Food-producing animals. Banned or restricted in the US and many other countries because of the human aplastic anemia concern and the risk of drug residues entering the food supply.
• Neonates and very young animals. Immature hepatic and renal function can prolong drug exposure. Use only with a veterinarian's direct supervision and monitoring.
• Animals with pre-existing bone marrow disease, anemia, or immune-mediated cytopenias. Any additional marrow suppression is likely to worsen the condition.
• Animals with significant liver disease. The liver metabolizes chloramphenicol, and impaired clearance increases systemic exposure.
• Animals on myelosuppressive drugs. Concurrent chemotherapy, immunosuppressants, or other marrow-toxic drugs increase the risk of severe cytopenias.
• Pregnant and lactating animals. Use only when the benefit clearly outweighs the risk and only under veterinary direction.
• Animals with known hypersensitivity to amphenicols. Cross-reactivity with florfenicol is possible and should be assumed until proven otherwise.

Drug Interactions

Chloramphenicol interacts with several drug classes:

• Cytochrome P450 substrates. Chloramphenicol inhibits hepatic cytochrome P450 enzymes in many species, which can increase plasma levels of co-administered drugs such as phenobarbital, warfarin, and some antiepileptics. This is one of the most clinically important interactions and can cause toxicity in the patient that has nothing to do with the infection.
• Other myelosuppressive agents. Additive marrow suppression is possible.
• Penicillins and cephalosporins. Chloramphenicol is bacteriostatic and can reduce the bactericidal effect of beta-lactam antibiotics in some in vitro models, though the clinical significance is debated. In serious infections, many clinicians avoid the combination.
• Rifampin. Can increase chloramphenicol metabolism in some species and reduce efficacy.

Always tell the veterinarian about every drug, supplement, and herbal product the animal receives before starting chloramphenicol.

Human Exposure and Handler Safety

Chloramphenicol is a human safety concern, not just a patient safety concern. Handlers who administer the drug to animals should handle it with care.

Key practices:

• Wear disposable gloves when handling capsules, suspensions, ointments, or any item that may carry drug residue, including pill pockets and syringes.
• Wash hands thoroughly with soap and water immediately after administration, even if gloves were worn.
• Do not crush tablets or open capsules in a way that creates dust, because inhalation is one route of exposure. If a compounded liquid is dispensed, use the supplied dosing device and avoid splashing.
• Pregnant women, women trying to conceive, and immunocompromised people should avoid handling chloramphenicol whenever possible. If no alternative handler is available, use double gloves and minimize contact time.
• Store the drug securely away from children and pets. Chloramphenicol has a bitter taste that reduces the risk of accidental pediatric ingestion, but it is not a safety feature.
• Dispose of unused drug properly. Follow local guidance for medication disposal to avoid environmental release. Chloramphenicol released into the environment participates in microbial degradation and resistance-gene exchange [1].
• Clean up spills with disposable towels and soap, and dispose of the towels in a sealed bag.

The concern is not theoretical. The association between chloramphenicol exposure and aplastic anemia in humans has been studied for decades, and although the epidemiologic results are inconsistent across countries and study designs [8][10][9], the precautionary stance in regulatory practice is justified by the idiosyncratic nature of the reaction.

Comparison with Alternatives

Florfenicol

Florfenicol is the veterinary-specific fluorinated analog of chloramphenicol. It replaces the hydroxyl group at C3 with fluorine, which prevents the drug from being a substrate for chloramphenicol acetyltransferase. That structural change is the reason florfenicol retains activity against many CAT-producing bacteria and does not carry the same human aplastic anemia concern. Florfenicol is approved for use in cattle, pigs, and some fish species in many countries, and it is the preferred amphenicol for food-producing animals where treatment is permitted. Florfenicol does not have the same systemic labeling in dogs and cats that chloramphenicol does, and it should not be substituted for chloramphenicol in companion animals without veterinary direction.

Doxycycline

For rickettsial infections such as Rocky Mountain spotted fever and ehrlichiosis, doxycycline is the treatment of choice in dogs and cats. It is safer, better studied, and lacks the human aplastic anemia risk. Chloramphenicol is a historical alternative, not a first-line option.

Metronidazole or Clindamycin

For anaerobic infections, metronidazole and clindamycin are commonly used and avoid the human safety concern. They may not cover the same gram-negative spectrum as chloramphenicol, so culture and sensitivity should guide selection.

Third-Generation Cephalosporins

For systemic gram-negative infections, drugs like ceftriaxone are often preferred in human and veterinary practice because of their bactericidal activity and safety profile. Interestingly, a Malawian study following the replacement of chloramphenicol with ceftriaxone as empiric therapy for suspected sepsis found that extended-spectrum beta-lactamase-producing Enterobacterales emerged rapidly, while chloramphenicol resistance in E. coli and Klebsiella species declined [3]. That study raised the possibility of reintroducing chloramphenicol as a reserve agent for critically ill human patients, and it is a useful reminder that antibiotic stewardship decisions are never one-directional.

Azithromycin

Used in some human typhoid and enteric fever regimens where chloramphenicol is an alternative. A study of ceftriaxone-resistant Salmonella Typhi from North India found the isolates remained sensitive to azithromycin and chloramphenicol, even when resistant to ceftriaxone, cefixime, ciprofloxacin, ampicillin, and co-trimoxazole [11]. That kind of susceptibility data is what makes chloramphenicol still relevant in specific settings.

Ophthalmic Alternatives

For topical ophthalmic use, chloramphenicol ointment competes with erythromycin, bacitracin, and fluoroquinolone ophthalmic preparations. A review of ophthalmic chloramphenicol resistance found mean resistance rates between 0% and 74.1%, with the majority of studies reporting rates below 50% and more than half below 20% [12]. The resistance picture is regional and antibiotic-specific, so a topical alternative may or may not be better depending on local flora.

Clinical Relevance, Limitations and Common Mistakes

Chloramphenicol remains in the veterinary formulary because of its broad spectrum, excellent tissue penetration, and activity against anaerobes and rickettsia. It is not a first-line drug for most routine infections, and it is not appropriate for food-producing animals in jurisdictions that ban it. The human safety concern is the single most important factor in the risk-benefit calculation.

Common mistakes to avoid:

1. Using it for a viral or non-bacterial condition. Chloramphenicol does not treat viral infections, and using it in those cases exposes the patient and the handler to risk without benefit.
2. Assuming any amphenicol is interchangeable with another. Florfenicol is not a direct substitute for chloramphenicol in companion animals, and chloramphenicol is not approved for the same species as florfenicol.
3. Failing to monitor a complete blood count on systemic therapy. Bone marrow suppression is dose-dependent and can be caught early with routine monitoring.
4. Skipping gloves during administration. The human exposure risk is real, and gloving is a simple, effective precaution.
5. Continuing the drug if the animal does not improve or worsens after 48 to 72 hours. A recheck and possibly a culture should guide the next step, not a longer course of the same drug.
6. Combining it with drugs that interact through cytochrome P450 without dose adjustment. This is a specific, preventable cause of toxicity.
7. Using human-labeled products on animals without veterinary oversight. Concentrations, excipients, and dosing schedules differ.
8. Disposing of unused drug in the trash or down the drain. Environmental release contributes to the resistance gene pool [1].

Individual cases require a veterinarian who can weigh the specific infection, the patient's health status, the handler's exposure risk, and local resistance patterns. This article is a framework, not a prescription.

Frequently Asked Questions

What is chloramphenicol used for in veterinary medicine?

Chloramphenicol is used for susceptible bacterial infections including respiratory, gastrointestinal, urinary, skin, ophthalmic, otic, and central nervous system infections. Its broad spectrum covers many gram-positive bacteria, gram-negative bacteria, anaerobes, and rickettsia, but it is not a first-line drug for most routine cases.

Is chloramphenicol safe for dogs and cats?

It can be used safely in dogs and cats under veterinary supervision, but it carries dose-dependent bone marrow suppression and a rare, idiosyncratic aplastic anemia risk that is not dose-dependent. Routine blood count monitoring is standard during systemic therapy.

Why is chloramphenicol banned in food-producing animals?

It is banned or heavily restricted in food-producing animals in the US and many other countries because of the human idiosyncratic aplastic anemia risk and the potential for drug residues in meat, milk, and eggs.

What is florfenicol and how is it different from chloramphenicol?

Florfenicol is a fluorinated analog of chloramphenicol developed for veterinary use. The fluorine substitution prevents inactivation by chloramphenicol acetyltransferase, and florfenicol has not been linked to the same human aplastic anemia concern. It is approved for use in several food-producing species where chloramphenicol is banned.

Can chloramphenicol cause aplastic anemia in my pet?

Aplastic anemia in animals has not been documented with the same frequency or certainty as in humans. The human concern is idiosyncratic and rare, and the veterinary risk is primarily dose-dependent bone marrow suppression that reverses when the drug is stopped.

Do I need to wear gloves when giving chloramphenicol to my pet?

Yes. Wear disposable gloves when handling capsules, suspensions, or ointments, wash your hands afterward, and never crush tablets in a way that creates inhalable dust. Pregnant or immunocompromised handlers should avoid handling the drug whenever possible.

How long does chloramphenicol take to work?

Owners often see improvement in clinical signs within 24 to 72 hours for susceptible infections. If the animal is not improving or is worsening after that window, contact the veterinarian for a recheck rather than extending the course.

Is topical chloramphenicol safer than the oral form?

Topical ophthalmic and dermatologic use has a much lower systemic exposure and has not been linked to aplastic anemia in the reviewed case data. It can still cause local reactions such as delayed hypersensitivity, and it should be used only as directed.

Related Articles

• Tylosin Antibiotic Diarrhea Dose: Antibiotic-Responsive Diarrhea Dose
• Cephalexin Weight-Based Antibiotic Dose Calculator: Veterinary Dosage Guide
• Amoxicillin Dog Cat Dose: Broad-Spectrum Antibiotic Weight-Based Guide
• Rimadyl Carprofen Dose: NSAID Anti-Inflammatory Dose and Safety
• Antimicrobial Stewardship in Canine Diarrhea: When Antibiotics Are Not the Answer
• Antimicrobial Stewardship in Canine Periodontal Disease: Antibiotic Use in Dentistry
• Amantadine for Dogs: Uses, Doses, and Safety
• Pepcid for Dogs: Dosage, Uses, and Safety Guide
• Clonidine for Dogs: Uses, Dosing, and Safety

Sources

1. Deciphering chloramphenicol biotransformation mechanisms and microbial interactions via integrated multi-omics and cultivation-dependent approaches.
2. Impeding pathways of intrinsic resistance in Escherichia coli confers antibiotic sensitization and resistance proofing.
3. Molecular mechanisms of re-emerging chloramphenicol susceptibility in extended-spectrum beta-lactamase-producing Enterobacterales.
4. Molecular Mechanisms of Drug Resistance in Staphylococcus aureus.
5. Prevalence and genetic basis of extended-spectrum β-lactamase-producing Escherichia coli carriage in broiler farms in the United Arab Emirates.
6. Detection of β-lactam and chloramphenicol resistance genes in Gram-negative bacteria isolated from Clarias gariepinus in selected aquaculture farms.
7. Efficacy and adverse effects of topical chloramphenicol ointment use for surgical wounds: a systematic review.
8. Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study.
9. Aplastic anemia in Brazil: incidence and risk factors.
10. The epidemiology of aplastic anemia in Thailand.
11. Ceftriaxone-resistant Salmonella Typhi isolated from paediatric patients in north India: Insights into genetic profiles and antibiotic resistance mechanisms.
12. Antibiotic resistance in ocular bacterial infections: an integrative review of ophthalmic chloramphenicol.